About GIPO
The GM-CSF Inhalation Promoting Organization (GIPO) is an organization working to overcome intractable respiratory diseases, such as pulmonary alveolar proteinosis, and improve the quality of life of patients. The organization is comprised mainly of doctors who have conducted clinical trials on GM-CSF inhalation therapy over many years and established clinical guidelines and treatment protocols.
We actively disseminate information in cooperation with related organizations so that the diagnosis and treatment of pulmonary alveolar proteinosis, for which GM-CSF inhalation therapy is now covered by the general health insurance system in Japan, can be received at any medical institution nationwide. We will contribute to the early diagnosis of pulmonary alveolar proteinosis, appropriate treatment, and improvement of patients' quality of life. We also promote research to expand new applications of GM-CSF inhalation therapy.
Outline
1.Awareness and optimization of GM-CSF inhalation therapy
- Awareness and treatment of GM-CSF inhalation therapy for patients with autoimmune pulmonary alveolar proteinosis.
- Support for conducting clinical research on optimizing inhalation methods, doses, and usage.
- Implementation of education and training for medical professionals.
2.Developmental research for new applications of GM-CSF inhalation therapy
- Support for conducting clinical research to explore the effectiveness and safety of GM-CSF inhalation therapy for diseases other than autoimmune pulmonary alveolar proteinosis.
3.Development of new applications of anti-GM-CSF autoantibody detection kit
- Supporting research to expand the application of anti-GM-CSF autoantibody testing to other diseases.
- Screening support for serum anti-GM-CSF autoantibody positive people after dust exposure.
4.Support for diagnosis and treatment of pulmonary alveolar proteinosis
- Revision of guidelines for diagnosis and treatment of pulmonary alveolar proteinosis
- Responding to inquiries from medical professionals
- Responding to consultations from patients in collaboration with the Japan Pulmonary Alveolar Proteinosis Patient Association
5.Collaboration with the Japanese Pulmonary Alveolar Proteinosis Patient Association
- Providing information for patient association activities
- Support for patient study sessions
- Recommendations to reflect in governmental policies and lobbying for system reform
We sincerely hope that GIPO's activities will help to improve the quality of life of patients who require GM-CSF inhalation therapy.
Chief Director, GM-CSF Inhalation Promoting Organization
Koh Nakata
Researcher Information
Koh Nakata
- researchmap
- KAKEN ‘Grant-in-Aid for Scientific Research Database’
- J-GLOBAL- Japan Science and Technology Agency
Ryushi Tazawa
- researchmap
- KAKEN ‘Grant-in-Aid for Scientific Research Database’
- J-GLOBAL- Japan Science and Technology Agency